About Science Partnerships News Careers Contact Pipeline Programs Target Discovery Sustainable Pipeline of Innovative Immunotherapies We are developing next-generation immunotherapies that leverage our single-cell technologies and provide unique insights into immunomodulation. Our sustainable pipeline of immunomodulatory antibodies targets multiple cell types and key immunosuppresive or inflammatory mechanisms for the treatment of cancer and autoimmune disease. OUR PIPELINE Target Evaluation Antibody Discovery Lead Antibody Identification Clinical Candidate Selection IND Enabling Studies Phase 1 Phase II Phase III HFB3010 HFB2003 HFB2009 HFB1002 HFB1011 HFB2006 HFB2012 HFB1014 HFB2015 We are exploring strategic partnerships for Enuzovimab (HFB30132A), a Delta variant active SARS-COV-2 neutralizing antibody with a completed Ph I healthy volunteer trial. Read more Immune Stimulatory Pathways Cell Depleting Immune Suppressive Pathways Discovery of Novel Targets Leading to a New Generation of Precision Immunotherapies We take a multi-faceted approach to target the immune system, including key immunosuppressive cell types, suppressive and stimulatory pathways, and pleiotropic immune modulators, to shift the immune balance in cancer and autoimmune diseases. Our target discovery approaches: Profiling of patient samples using our Drug Intelligent Science (DIS™) single-cell capabilities Collaborations with leading immunology and oncology key opinion leaders Target deconvolution using patients’ antibody repertoires About Science Partnerships News Careers Contact © HiFiBiO Therapeutics, 2021. All Rights Reserved. Privacy Policy Manage cookie settings